GlassScriptPhysician profile
Jacqueline A Burkhardt
NPI 1902842933
$3,439.67
in general payments reported to CMS, 2019-2025
23 companies · $618 in 2025
The $618 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $267 · 2021: $336 · 2022: $707 · 2023: $525 · 2024: $486 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $369.92 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $368.55 | 2022-2025 | Acuvue |
| Alcon Vision LLC | $336.14 | 2021-2025 | Total30, Precision7, Tryptyr |
| Oyster Point Pharma, INC. | $327.67 | 2022-2025 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $289.87 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $270.02 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $241.53 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $226.01 | 2022-2025 | Infuse, Miebo, Xiidra |
| Visioneering Technologies, INC. | $191.38 | 2019-2025 | |
| Allergan, INC. | $188.08 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $170.45 | 2019-2022 | |
| Coopervision INC. | $105.26 | 2023-2025 | Myday Contact Lens, Misight Contact Lens, Paragon Crt |
| Shire North American Group INC | $64.95 | 2019 | |
| Amgen INC. | $63.32 | 2024 | Tepezza |
| Harrow Eye, LLC | $47.62 | 2025 | Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $33.31 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $27.83 | 2022 | |
| Thea Pharma INC. | $23.85 | 2025 | Iyuzeh |
| Abb Con-Cise Optical Group LLC | $23.07 | 2023 | Contact Lens, Spectacle Lenses |
| Abbvie INC. | $18.96 | 2022 | |
| Astellas Pharma US INC | $18.95 | 2025 | Izervay |
| Rxsight INC | $17.12 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Optos, INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Burkhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.